Advanced Search

 

Study ID Status Title Patient Level Data
580299/004 Completed Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine against Human Papillomavirus Types 16 and 18, when Formulated with Aluminum Hydroxide, AS04, or without Adjuvant, in Healthy Adult Female Volunteers Study Listed on ClinicalStudyDataRequest.com
580299/005 Completed A Phase II Double-Blind, Randomized, Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, in Healthy Adult Female Volunteers Study Listed on ClinicalStudyDataRequest.com
580299/007 Completed Study of the efficacy of candidate HPV 16/18 VLP vaccine in the prevention of HPV-16 and/or HPV-18 cervical infection in adolescent & young adult women in North America and Brazil vaccinated in primary study 580299/001 Study Listed on ClinicalStudyDataRequest.com
580299/008 Completed A phase III, double-blind, randomized, controlled, multi-center study to evaluate the efficacy of GlaxoSmithKline Biologicals. HPV-16/18 VLP AS04 vaccine compared to hepatitis A vaccine as control in prevention of persistent HPV-16 or HPV-18 cervical infection and cervical neoplasia, administered intramuscularly according to a 0, 1, 6 month schedule in healthy females 15-25 years of age. Study Listed on ClinicalStudyDataRequest.com
580299/011 Completed An observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy male subjects aged 10-18 years Study Listed on ClinicalStudyDataRequest.com
580299/012 Completed Immunogenicity: 3 consecutive lots of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly at 0,1,6 month schedule in healthy females aged 10–25 years and demonstrate non-inferiority of candidate HPV vaccine manufactured by modified production process Study Listed on ClinicalStudyDataRequest.com
580299/013 Completed Evaluate the safety and immunogenicity of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly according to a 0,1,6 month schedule in healthy female subjects (10 – 14 years) Study Listed on ClinicalStudyDataRequest.com
63119 Completed A double blind, randomized, controlled, dose ranging study of Org31540/SR90107A in patients with unstable angina pectoris: PENTUA
63128 Completed A phase I interaction trial to investigate the pharmacodynamics and pharmacokinetics of 10 mg subcutaneous Org31540/SR90107A and intravenous recombinant Factor VIIa, in healthy male volunteers.
63132 Completed A phase I trial to evaluate and compare the safety, pharmacokinetics and pharmacodynamics of a single dose of 7.5mg subcutaneous Org31540/SR90107A in subjects with moderate hepatic impairment and subjects with normal liver function
675187/001 Completed A Phase II, open, randomized, controlled study to evaluate the reactogenicity and safety of an investigational vaccination regimen in healthy toddlers aged 24-30 months. Study Listed on ClinicalStudyDataRequest.com
684289/001 Completed A phase IV, open, randomised study in adults aged 18-60 and over 60 years to evaluate the immunogenicity and the reactogenicity of GlaxoSmithKline Biologicals' Fluarix™ vaccine administered using two different routes Study Listed on ClinicalStudyDataRequest.com
701464/005 Completed A phase III, open, controlled, randomised study in adults aged 18-60 and elderly aged over 60 years to confirm the immunogenicity and the reactogenicity of GlaxoSmithKline Biologicals' investigational influenza vaccine Study Listed on ClinicalStudyDataRequest.com
710158/002 Completed A primary vaccination study to evaluate immunogenicity, safety and reactogenicity of 3 doses of GSK Biologicals/Finlay’s meningococcal B candidate vaccine given intramuscularly using either 0-2-4 month or 0-1-6 month schedule to healthy subjects aged 12-18 years Study Listed on ClinicalStudyDataRequest.com
711202/001 Completed Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals’ MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals’ Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life Study Listed on ClinicalStudyDataRequest.com
711202/008 Completed Evaluate the persistence and immune memory induced by a primary vaccination course with GSK Biologicals’ MenC-TT (1 formulation) & GSK Biologicals’ Hib-MenC-TT (2 formulations) or Meningitec™ in healthy toddlers aged 12-15 months primed in study 711202/001 Study Listed on ClinicalStudyDataRequest.com
711866/001 Completed A study to assess the lot-to-lot consistency of GSK Biologicals dTpa-IPV vaccine administered to healthy children 4 to 8 years of age, previously vaccinated with four doses of DTPa or DTPa-based combination vaccines and at least 3 doses of OPV or IPV Study Listed on ClinicalStudyDataRequest.com
711866/002 Completed Open, randomised, multicenter, Phase II clinical trial to assess the immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals' dTpa-IPV vaccine compared to GSK Biologicals' dTpa (Boostrix™) and Aventis Pasteur Merck Sharp Dohme’s (MSD) IPV (Imovax Polio®) vaccines administered separately, and to assess immunogenicity and reactogenicity of GSK Biologicals' DTPa-IPV vaccine (Infanrix-IPV™), when administered to healthy adolescents aged 10-14 years. Study Listed on ClinicalStudyDataRequest.com
711866/003 Completed Assess immunogenicity, reactogenicity of GSK Biologicals’-dTpa-IPV vaccine versus dTpa & IPV vaccines administered separately & compared with Aventis Pasteur MSD’s Td-IPV vaccine when administered to healthy adolescents & adults Study Listed on ClinicalStudyDataRequest.com
711866/005 Completed Open, 1-year, phase III, immunogenicity follow-up of subjects who previously received GSK Biologicals’ dTpa-IPV vaccine or GSK Biologicals’ dTpa (BoostrixTM) and Pasteur Mérieux’s IPV vaccine (IPV Mérieux() administered separately, at 4 to 8 years of age in study 711866/001 (dTpa-IPV-001)
711866/006 Completed A phase III, open study to evaluate the immunogenicity, safety and reactogenicity of GSK Bios’ dTpa-IPV vaccine when administered as a booster vaccination to healthy children (6-8 Y) and previously vaccinated with 4 doses of DTPw and at least 3 doses of OPV/ IPV vaccines
712753/001 Completed A Bioequivalence Study with a Combination Tablet Formulation of Rosiglitazone and Metformin (4mg/1000mg) Compared to the Commercial Tablet Formulation of AVANDAMET (2mg rosiglitazone/500mg metformin) and a Dose Proportionality Study Comparing the Combination Tablet Formulations of Rosiglitazone and Metformin (4mg/1000mg & 2mg/1000mg). Study Listed on ClinicalStudyDataRequest.com
712753/002 Completed A phase III, 24 week, multi-centre, randomised, double-blind, parallel group, dose escalation study of Avandamet (rosiglitazone/metformin) and high dose metformin monotherapy in subjects with poorly controlled type 2 diabetes mellitus Study Listed on ClinicalStudyDataRequest.com
712753/003 Completed A Phase III Multi-Centre, Double-Blind, Randomised, Parallel-Group, Dose Escalation Study Comparing the Effects of 32 Weeks Administration of Avandamet and Metformin on Hba1c Targets in Subjects With Mild Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
712753/004 Completed An open-label trial to evaluate the safety and efficacy of fixed dose rosiglitazone/metformin combination therapy in poorly-controlled subjects with type 2 diabetes mellitus Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.